-
Je něco špatně v tomto záznamu ?
Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats
Josef Zicha, Zdenka Dobešová, Jaroslav Kuneš
Jazyk angličtina Země Japonsko
Typ dokumentu práce podpořená grantem
Grantová podpora
NR7786
MZ0
CEP - Centrální evidence projektů
PubMed
17378375
DOI
10.1291/hypres.29.1021
Knihovny.cz E-zdroje
- MeSH
- acetylcystein farmakologie terapeutické užití MeSH
- antihypertenziva farmakologie terapeutické užití MeSH
- hypertenze chemicky indukované prevence a kontrola MeSH
- kaptopril farmakologie terapeutické užití MeSH
- krevní tlak účinky léků MeSH
- krysa rodu rattus MeSH
- NG-nitroargininmethylester antagonisté a inhibitory farmakologie MeSH
- nitroprusid farmakologie terapeutické užití MeSH
- pentoliniumtartrát farmakologie terapeutické užití MeSH
- potkani Wistar MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
Hypertension due to chronic inhibition of NO synthase (NOS) by Nomega-nitro-L-arginine methyl ester (L-NAME) administration is characterized by both impaired NO-dependent vasodilation and enhanced sympathetic vasoconstriction. The aim of our study was to evaluate changes in the participation of major vasoactive systems in L-NAME-treated rats which were subjected to simultaneous antihypertensive (captopril) or antioxidant (N-acetylcysteine, NAC) treatment. Three-month-old Wistar males treated with L-NAME (60 mg/kg/day) for 5 weeks were compared to rats in which L-NAME treatment was combined with simultaneous chronic administration of captopril or NAC. Basal blood pressure (BP) and its acute responses to consecutive i.v. injections of captopril (10 mg/kg), pentolinium (5 mg/kg), L-NAME (30 mg/kg), tetraethylammonium (TEA, 16 mg/kg) and nitroprusside (NP, 20 microg/kg) were determined in conscious rats at the end of the study. The development of L-NAME hypertension was prevented by captopril treatment, whereas NAC treatment caused only a moderate BP reduction. Captopril treatment normalized the sympathetic BP component and significantly reduced residual BP (measured at full NP-induced vasodilation). In contrast, chronic NAC treatment did not modify the sympathetic BP component or residual BP, but significantly enhanced NO-dependent vasodilation. Neither captopril nor NAC treatment influenced the compensatory increase of TEA-sensitive vasodilation mediated by endothelium-derived hyperpolarizing factor in L-NAME-treated rats. Chronic captopril treatment prevented L-NAME hypertension by lowering of sympathetic tone, whereas chronic NAC treatment attenuated L-NAME hypertension by reduction in the vasodilator deficit due to enhanced NO-dependent vasodilation.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13028316
- 003
- CZ-PrNML
- 005
- 20130905091113.0
- 007
- ta
- 008
- 130902s2006 ja d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1291/hypres.29.1021 $2 doi
- 035 __
- $a (PubMed)17378375
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Zicha, Josef, $d 1950- $7 jk01152609 $u Institute of Physiology AS CR and Cardiovascular Research Center, Prague, Czech Republic
- 245 10
- $a Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats / $c Josef Zicha, Zdenka Dobešová, Jaroslav Kuneš
- 504 __
- $a Literatura
- 520 9_
- $a Hypertension due to chronic inhibition of NO synthase (NOS) by Nomega-nitro-L-arginine methyl ester (L-NAME) administration is characterized by both impaired NO-dependent vasodilation and enhanced sympathetic vasoconstriction. The aim of our study was to evaluate changes in the participation of major vasoactive systems in L-NAME-treated rats which were subjected to simultaneous antihypertensive (captopril) or antioxidant (N-acetylcysteine, NAC) treatment. Three-month-old Wistar males treated with L-NAME (60 mg/kg/day) for 5 weeks were compared to rats in which L-NAME treatment was combined with simultaneous chronic administration of captopril or NAC. Basal blood pressure (BP) and its acute responses to consecutive i.v. injections of captopril (10 mg/kg), pentolinium (5 mg/kg), L-NAME (30 mg/kg), tetraethylammonium (TEA, 16 mg/kg) and nitroprusside (NP, 20 microg/kg) were determined in conscious rats at the end of the study. The development of L-NAME hypertension was prevented by captopril treatment, whereas NAC treatment caused only a moderate BP reduction. Captopril treatment normalized the sympathetic BP component and significantly reduced residual BP (measured at full NP-induced vasodilation). In contrast, chronic NAC treatment did not modify the sympathetic BP component or residual BP, but significantly enhanced NO-dependent vasodilation. Neither captopril nor NAC treatment influenced the compensatory increase of TEA-sensitive vasodilation mediated by endothelium-derived hyperpolarizing factor in L-NAME-treated rats. Chronic captopril treatment prevented L-NAME hypertension by lowering of sympathetic tone, whereas chronic NAC treatment attenuated L-NAME hypertension by reduction in the vasodilator deficit due to enhanced NO-dependent vasodilation.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a acetylcystein $x farmakologie $x terapeutické užití $7 D000111
- 650 02
- $a zvířata $7 D000818
- 650 02
- $a antihypertenziva $x farmakologie $x terapeutické užití $7 D000959
- 650 02
- $a krevní tlak $x účinky léků $7 D001794
- 650 02
- $a kaptopril $x farmakologie $x terapeutické užití $7 D002216
- 650 02
- $a hypertenze $x chemicky indukované $x prevence a kontrola $7 D006973
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a NG-nitroargininmethylester $x antagonisté a inhibitory $x farmakologie $7 D019331
- 650 02
- $a nitroprusid $x farmakologie $x terapeutické užití $7 D009599
- 650 02
- $a pentoliniumtartrát $x farmakologie $x terapeutické užití $7 D010425
- 650 02
- $a krysa rodu Rattus $7 D051381
- 650 02
- $a potkani Wistar $7 D017208
- 650 02
- $a Tetraethylammonium $x pd [Pharmacology]
- 650 02
- $a Tetraethylammonium $x tu [Therapeutic Use]
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dobešová, Zdena, $d 1947- $7 xx0074152 $u Institute of Physiology AS CR and Cardiovascular Research Center, Prague, Czech Republic
- 700 1_
- $a Kuneš, Jaroslav, $d 1948- $7 nlk19990073450 $u Institute of Physiology AS CR and Cardiovascular Research Center, Prague, Czech Republic
- 773 0_
- $t Hypertension Research - Clinical & Experimental $x 0916-9636 $g Roč. 29, č. 12 (2006), s. 1021-1027 $p Hypertens Res $w MED00006041
- 773 0_
- $p Hypertens Res $g 29(12):1021-7, 2006 Dec $x 0916-9636
- 910 __
- $a ABA008 $y 3 $z 0
- 990 __
- $a 20130902140339 $b ABA008
- 991 __
- $a 20130905091602 $b ABA008
- 999 __
- $a ok $b bmc $g 992294 $s 826748
- BAS __
- $a 3
- BMC __
- $x MED00006041 $i 0916-9636 $a 2006 $b 29 $c 12 $d 1021-1027 $m Hypertension research
- GRA __
- $a NR7786 $p MZ0
- LZP __
- $a 2013-09/gvbo